Table 1.
ECHO and THRIVE: baseline characteristics of patients according to HBV and/or HCV coinfection status at baseline (N = 1335)
| Parameter | HIV patients with HBV/HCV coinfection |
HIV patients without HBV/HCV coinfection |
||
|---|---|---|---|---|
| 25 mg of RPV once daily, N = 49 | 600 mg of EFV once daily, N = 63 | 25 mg of RPV once daily, N = 621 | 600 mg of EFV once daily, N = 602 | |
| Patient demographics | ||||
| male, % | 77.6 | 73.0 | 75.2 | 76.4 |
| Caucasian/white, % | 46.9 | 50.8 | 62.6 | 60.6 |
| age (years), median (range) | 38 (25–78) | 35.5 (22–63) | 36 (18–74) | 36 (19–69) |
| Disease characteristics | ||||
| HIV-1 viral load (log10 copies/mL), median (range) | 5.2 (3.2–6.2) | 5.0 (3.2–6.1) | 4.9 (2.2–7.3) | 5.0 (3.0–6.7) |
| HIV-1 viral load >100 000 copies/mL, % | 61.2 | 47.6 | 44.8 | 51.8 |
| CD4 count (cells/mm3), mean (95% CI) | 230 (198–263) | 246 (216–276) | 262 (251–273) | 274 (262–285) |
| CDC category C, % | 8.2 | 4.8 | 4.5 | 5.8 |
RPV, rilpivirine; EFV, efavirenz.